Anti-IL-33 antibody treatment inhibits airway inflammation in a murine model of allergic asthma

Biochem Biophys Res Commun. 2009 Aug 14;386(1):181-5. doi: 10.1016/j.bbrc.2009.06.008. Epub 2009 Jun 7.


Interleukin (IL)-33 is a recently described member of the IL-1 family and has been shown to induce production of T helper type 2 cytokines. In this study, an anti-IL-33 antibody was evaluated against pulmonary inflammation in mice sensitized and challenged with ovalbumin. The anti-IL-33 or a control antibody (150 microg/mouse) was given intraperitoneally as five doses before the sensitization and antigen challenge. Treatment with anti-IL-33 significantly reduced serum IgE secretion, the numbers of eosinophils and lymphocytes, and concentrations of IL-4, IL-5, and IL-13 in bronchoalveolar lavage fluid compared with administration of a control antibody. Histological examination of lung tissue demonstrated that anti-IL-33 significantly inhibited allergen-induced lung eosinophilic inflammation and mucus hypersecretion. Our data demonstrate for the first time that anti-IL-33 antibody can prevent the development of asthma in a mouse model and indicate that blockade of IL-33 may be a new therapeutic strategy for allergic asthma.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antibodies / therapeutic use*
  • Asthma / immunology
  • Asthma / therapy*
  • Bronchoalveolar Lavage Fluid / immunology
  • Cytokines / biosynthesis
  • Disease Models, Animal
  • Female
  • Immunoglobulin E / blood
  • Interleukin-33
  • Interleukins / antagonists & inhibitors*
  • Interleukins / immunology
  • Mice
  • Mice, Inbred BALB C
  • Ovalbumin / immunology
  • Pneumonia / immunology
  • Pneumonia / pathology
  • Pneumonia / therapy*
  • Th1 Cells / immunology
  • Th2 Cells / immunology


  • Antibodies
  • Cytokines
  • Il33 protein, mouse
  • Interleukin-33
  • Interleukins
  • Immunoglobulin E
  • Ovalbumin